Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
7.9.2023 10:00:00 EEST | Business Wire | Press release
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/
CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.
Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.
CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.
Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.
CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.
Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.”
Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: “ We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.
We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.
Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.
For more information visit www.cerbaresearch.com
About CIRION
CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).
Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907759314/en/
Contact information
Press contacts:
Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com
CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Announced its Q1’2026 Results Presenting Accelerated Growth in the Specialty Ingredients & Solutions Activity11.5.2026 13:03:00 EEST | Press release
Tsahi Barak, Chairman of the Board and CEO of the Company, stated: “We are pleased to report a strong quarter during which we continued to successfully implement the company’s business strategy, which emphasizes, among other things, significant and profitable growth in the Specialty Ingredients & Solutions activity and the expansion of Solos’ infrastructure, our dealcoholization division. We believe that the positive momentum in this activity will continue throughout the year, as we continuously work to leverage the many opportunities across the various markets. The company is very active across several strategic initiatives and since the beginning of the year, we have announced several business developments, including the acquisition of the Brazilian natural extracts company Sylvestre, whose contribution is not yet reflected in our reported financial results. We are in an excellent position to continue realizing opportunities to accelerate the Company’s growth and strengthen its posit
Corpay Partners With BVNK To Add Stablecoin Wallets for Global Customers11.5.2026 13:00:00 EEST | Press release
Corpay, Inc. (NYSE: CPAY), the leading corporate payments company, today announced that it is partnering with stablecoin infrastructure platform BVNK to provide stablecoin wallets and settlement capabilities to its global customer base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511711546/en/ The integration will enable Corpay’s customers to see a stablecoin balance alongside their fiat balances, and provide customers with embedded stablecoin wallets for sending, receiving, storing, and converting stablecoins within its platform. Customers will now have access to the always-on payment rails that operate beyond the limits of traditional banking hours and systems. Corpay will also integrate stablecoin rails in its treasury operations, reducing reliance on pre-funded accounts, improving capital efficiency, and improving the movement of funds across its global footprint outside of its own proprietary network. Corpay serve
Ant International Highlights Democratising AI and Strengthening Trust in 2025 Sustainability Report11.5.2026 12:17:00 EEST | Press release
Ant International, a leading global digital payment, digitisation and financial technology provider, today published its 2025 Sustainability Report, the 2nd since the Company began independent operation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511086227/en/ This is also the first year Ant International integrated sustainability metrics into the management's performance evaluation framework. As Eric Jing, Chairmanof Ant Group and Ant International said, “Accountability must be structural, not aspirational. When sustainability outcomes are valued as much as revenue growth or operational efficiency, the whole organisation is more likely to align accordingly-just like how it might work with entire economies.” In the Company’s 6Ts Sustainability Framework (Travel, Trade, Thrive, Tech, Talent, Trust),Inclusion remains the critical objective. “Our success relies on our ability to innovate for small businesses and emerging
Dryad Launches Gen-4-Pro Silvanet Wildfire Sensor, Setting New Standard in Ultra-Early Fire Detection11.5.2026 12:09:00 EEST | Press release
Dryad Networks, a global leader in ultra-early wildfire detection technology, today announced the launch and immediate availability of the Gen-4-Pro Silvanet Wildfire Sensor, the fourth generation of its industry-leading Silvanet solution. The new Gen-4-Pro sensor introduces significant advancements in detection capability, energy autonomy, and connectivity—further strengthening Dryad’s mission to protect forests, infrastructure, and communities from the growing threat of wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260510819235/en/ Silvanet Wildfire Sensor Gen4Pro enables ultra-early wildfire detection and environmental data monitoring. The Silvanet suite is a comprehensive wildfire detection system combining solar-powered gas sensors, a large-scale wireless IoT network, and cloud-based analytics. Unlike traditional camera or satellite-based systems, Silvanet detects wildfires within minutes of ignition—often d
Macnica ATD Europe Acquires Indesmatech to Deepen Engineering Presence Across Northern Europe11.5.2026 12:00:00 EEST | Press release
Macnica ATD Europe today announced the acquisition of Indesmatech, a pan-European technology and advisory company specializing in advanced semiconductor representation, design-in support and consulting, as well as point click buying services. The acquisition is a strategic move by Macnica ATD Europe to strengthen its commercial and engineering presence across Scandinavia and Northern Europe, adding established regional relationships, in-house engineering capabilities and a proven ecosystem-led approach in line with its already strong presence in the region. It’s business focus areas include IoT, communications and power, embedded computing, memory and ASIC, and audio and sensing applications. This complements Macnica ATD Europe’s existing portfolio and reinforces its ability to support customers across a wide range of technology-driven markets. The two companies' go-to-market models are closely aligned. Macnica ATD Europe takes an architecture-driven solutions approach, which goes beyo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom